Research

Energy balance

If 1%, 5%, or 10% of the population aged 60 years or older is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively.

Understanding these cost projections is crucial for policymakers and healthcare planners.

StrongSupportsmedium confidence
If 1%, 5%, or 10% of this population is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively.
Timothy Nguyen et al. · American Journal of Therapeutics · 2023

Why this rating

The claim is based on projected data provided in the abstract.

Source

Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity

Timothy Nguyen et al. · American Journal of Therapeutics · 2023

DOI 10.1097/mjt.0000000000001643

reviewCited 6×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →